Evelo Biosciences has filed a patent for methods and pharmaceutical compositions involving Fournierella massiliensis bacteria and microbial extracellular vesicles (mEVs) as therapeutic agents. The patent claim specifically focuses on a pharmaceutical composition comprising Fournierella massiliensis bacteria. GlobalData’s report on Evelo Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Evelo Biosciences, Peptide pharmacophores was a key innovation area identified from patents. Evelo Biosciences's grant share as of September 2023 was 5%. Grant share is based on the ratio of number of grants to total number of patents.
Therapeutic use of fournierella massiliensis bacteria
A recently filed patent (Publication Number: US20230302061A1) describes a pharmaceutical composition comprising Fournierella massiliensis bacteria. The composition can include different strains of Fournierella massiliensis, with varying levels of genomic, 16S, and/or CRISPR sequence identity to a specific nucleotide sequence. The patent also covers compositions with different percentages of Fournierella massiliensis bacteria, ranging from at least 50% to substantially all of the bacteria in the composition. The bacterial composition can be in the form of live, attenuated, or killed bacteria, and can also be lyophilized or irradiated.
Additionally, the patent describes a pharmaceutical composition comprising isolated extracellular vesicles (mEVs) produced from Fournierella massiliensis. Similar to the bacterial composition, the mEVs composition can include different strains of Fournierella massiliensis with varying levels of sequence identity. The patent also covers compositions where a certain percentage of the total particles or proteins in the composition are Fournierella massiliensis mEVs.
The pharmaceutical compositions described in the patent are intended for the treatment of various diseases, including immune disorders, inflammatory disorders, dysbiosis, and cancer. The compositions can induce an immune response and activate innate antigen presenting cells. They can be formulated for different routes of administration, such as oral, rectal, sublingual, intradermal, intraperitoneal, or subcutaneous administration. The compositions can be in the form of solid dose forms (e.g., tablets, capsules) or suspensions, and may include additional therapeutic agents. The patent also covers methods of preparing the pharmaceutical compositions, as well as methods of treating subjects in need of the described treatments.
Overall, the patent describes the use of Fournierella massiliensis bacteria and microbial extracellular vesicles for the development of pharmaceutical compositions with potential therapeutic applications in various diseases.
To know more about GlobalData’s detailed insights on Evelo Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
